Skip to main content
Figure 3 | AIDS Research and Therapy

Figure 3

From: Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

Figure 3

Distribution of side effects with regards to different CYP2B6 516G > T genotypes. *Based on their questionnaires, subjects were grouped into those with no side effects (Group1), those with mild symptoms (1-12 points- Group2), with moderate symptoms (13-48 points -Group3) and with severe side effects (> 48 points or presence of hallucinations or psychotic episodes-Group 4). Please refer to text for further detail. GG (n = 29): 24% (n = 7) no side effects reported; 59% (n = 17) mild side effects; 17% (n = 5) moderate side effects; none with severe side effects. GT (n = 33): 15%(n = 5) no side effects; 55% (n = 18) mild side effects; 27% (n = 9) moderate side effects; 3% (n = 1) severe side effects TT (n = 18): 5% (n = 1) no side effects; 56% (n = 10) mild side effects; 28% (n = 5) moderate side effects. 11% (n = 2) severe side effects. (Refer appendix for patient questionnaire).

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us